D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

D. E. Shaw & Co. Inc. lessened its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 43.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 188,583 shares of the biotechnology company's stock after selling 146,198 shares during the period. D. E. Shaw & Co. Inc. owned 0.32% of Aldeyra Therapeutics worth $941,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth about $52,000. Balyasny Asset Management L.P. bought a new position in Aldeyra Therapeutics in the 4th quarter valued at about $56,000. Catalyst Funds Management Pty Ltd raised its holdings in Aldeyra Therapeutics by 2,083.3% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock valued at $65,000 after acquiring an additional 12,500 shares during the period. Regal Investment Advisors LLC acquired a new stake in Aldeyra Therapeutics during the fourth quarter worth approximately $66,000. Finally, Walleye Capital LLC acquired a new stake in Aldeyra Therapeutics during the fourth quarter worth approximately $68,000. Institutional investors and hedge funds own 59.71% of the company's stock.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ:ALDX traded up $0.06 on Thursday, reaching $2.28. 598,033 shares of the company's stock were exchanged, compared to its average volume of 791,858. Aldeyra Therapeutics, Inc has a twelve month low of $1.14 and a twelve month high of $7.20. The company has a fifty day moving average of $2.76 and a 200-day moving average of $4.54. The company has a market capitalization of $136.56 million, a price-to-earnings ratio of -2.35 and a beta of 0.92. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.08. On average, research analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Aldeyra Therapeutics to a "sell" rating in a research note on Wednesday, May 21st. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Monday, May 19th. Finally, BTIG Research dropped their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Monday, April 7th.

Insider Activity at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares in the company, valued at $8,343,708.42. This represents a 36.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.60% of the stock is owned by insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.